Lacutoclax clinical trials
Also written LP-108.
How each study uses lacutoclax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lacutoclax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Guangzhou Lupeng Pharmaceutical Company LTD. (3) · Newave Pharmaceutical Inc (1) · The First Affiliated Hospital with Nanjing Medical University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lacutoclax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLRecruitingPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT05641259Written as LP-108
- A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLLRecruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07609823Written as Lacutoclax
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingPhase 1/2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07609862Written as Lacutoclax+Rocbrutinib
- Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AMLCompletedPhase 1Newave Pharmaceutical IncNCT04139434Written as LP-108
- A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownPhase 1The First Affiliated Hospital with Nanjing Medical UniversityNCT04356846Written as LP-108 tablet
Codes
What other systems call lacutoclax · ClinicalTrials.gg INT017597
- UNII (FDA) PMG5245L91LACUTOCLAXOne source FDA
- NCI Thesaurus C203075LacutoclaxOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PMG5245L91 | LACUTOCLAX | One source FDA |
| NCI Thesaurus | C203075 | Lacutoclax | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.